We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

43 hedge funds and large institutions have $13.4M invested in NeuBase Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

4% less funds holding

Funds holding: 45 → 43 (-2)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

42% less capital invested

Capital invested by funds: $23.3M → $13.4M (-$9.88M)

Holders
43
Holders Change
-2
Holders Change %
-4.44%
% of All Funds
0.72%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
5
Increased
6
Reduced
7
Closed
7
Calls
$14K
Puts
–
Net Calls
+$14K
Net Calls Change
-$27K

Top Buyers

1
KAS
Kestra Advisory Services
Texas
+$599K
2
CM
CM Management
Florida
+$52.8K
3
JAMONY
Jacob Asset Management of New York
California
+$51.7K
4
Charles Schwab
Charles Schwab
California
+$34.9K
5
Renaissance Technologies
Renaissance Technologies
New York
+$28.5K

Top Sellers

1
Bank of New York Mellon
Bank of New York Mellon
New York
-$164K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$77.4K
3
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$70K
4
Two Sigma Advisers
Two Sigma Advisers
New York
-$48K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$34K
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$32K +$34.9K +1,486 New
KAM
27
Knightsbridge Asset Management
California
$23K +$13.9K +591 +112%
Bank of America
28
Bank of America
North Carolina
$17K – – –
OC
29
Oppenheimer & Co
New York
$17K – – –
WP
30
WealthSource Partners
California
$15K -$11.1K -475 -40%
First Manhattan
31
First Manhattan
New York
$14K – – –
HWA
32
Heritage Wealth Advisors
Virginia
$11K – – –
UBS Group
33
UBS Group
Switzerland
$3K +$2.89K +123 New
TRCT
34
Tower Research Capital (TRC)
New York
$2K -$11.9K -506 -84%
CSS
35
Cubist Systematic Strategies
Connecticut
$2K -$798 -34 -27%
VVP
36
Venture Visionary Partners
Ohio
$698 +$774 +33 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
– -$164K -4,361 Closed
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
– -$70K -1,871 Closed
Two Sigma Advisers
39
Two Sigma Advisers
New York
– -$48K -1,268 Closed
Susquehanna International Group
40
Susquehanna International Group
Pennsylvania
– -$34K -917 Closed
Millennium Management
41
Millennium Management
New York
– -$33K -869 Closed
Two Sigma Investments
42
Two Sigma Investments
New York
– -$19K -511 Closed
Simplex Trading
43
Simplex Trading
Illinois
– -$6.24K -266 Closed
Morgan Stanley
44
Morgan Stanley
New York
– -$915 -39 -76%
SSA
45
Schonfeld Strategic Advisors
New York
– +$14.9K +636 New
1
2

NBSE Hedge Fund Activity: Q2 2022 in Review

43 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q2 2022, worth a combined $13.4M — down 42% from $23.3M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of NBSE and 5 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 6 added.

The largest buyer was Kestra Advisory Services, opening a new position worth an estimated $599K. The largest seller was Bank of New York Mellon, exiting entirely with an estimated $164K sold.

  • 43 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q2 2022, down from 45 in Q1 2022.
  • Funds reported $13.4M of NeuBase Therapeutics, Inc. Common Stock stock for Q2 2022, down 42% quarter-over-quarter.
  • 5 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q2 2022 and 7 closed out, a net change of -2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q2 2022 was Kestra Advisory Services, an estimated $599K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q2 2022 was Bank of New York Mellon, an estimated $164K sold.

Based on aggregated 13F filings for Q2 2022.